Coya Therapeutics, Inc.
COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candā¦ read more
Healthcare
Biotechnology
3 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.87
Price+0.21%
$0.01
1Y
Price
Market Cap
$114.236m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-2868.5%
EBITDA Margin-2869.6%
Net Profit Margin-2472.0%
Free Cash Flow Margin-2868.5%
EBITDA Margin-2869.6%
Net Profit Margin-2472.0%
Free Cash Flow MarginRevenue
$7.939m
-0.1%
1y CAGR+27.6%
3y CAGR+20.7%
5y CAGREarnings
-$21.126m
+0.5%
1y CAGR-42.8%
3y CAGR-23.4%
5y CAGREPS
-$1.15
+9.5%
1y CAGR-14.7%
3y CAGR-2.1%
5y CAGRBook Value
$48.970m
$53.271m
Assets$4.301m
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
-$14.120m
-31.5%
1y CAGR-9.3%
3y CAGR-20.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company